1Winchester DP, Jeske JM, Goldschmldt RA. The diagnosis and management of ductal carcinoma insitu of the breast [ J ] . CA Cancer J Clin, 2000, 50 ( 3 ) : 184 - 200.
3Petit T, Wilt M, Velten M, et al. comparative value of tumourglade hormonal receptors, ki- 67, HER -2 and topoisomer -ase II alpha status as predictive makeres in breast cancer patients treated with neoadjuvant athracyclinebased chemotherapy [ J ] . Eur J Cancer, 2004,40(2) :205-211.
4Chow LWC. Loo WTY . Partialbreast treatment for early breast cancer:emergence of a new paradigm[J ]. Nat Clin Pract Oncol,2005,2( 1 ) :40 -47.
5Sanidas EE. Daskalakis M, Sbyrakis N, et al. Modifications of the learning curve guidelines for breastcancer sentinel node biopsy [ J ] . Eur J Surg Oncol, 2005,31 (4) : 357 - 363.
6Bonadonna G, Valagussa P, Brabilla C. et al. Primary chemo therapy in operable breast cancer, eight-year experience at the Mi- lan Cancer Institute [ J ]. J Clin Oncol, 1998,16(1) :93-100.
2Venturino A, Comandini D, Granetto C, et al. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability[J].Breast Cancer Res Treat, 2000,62(3):217.
3Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,14(9):1391.
4Dowsett M. Biological background to aromatase inhibition[J].Breast,1996,5:196.
5Gegra J. C. Mechanism of action of progestational agents[J].Semin Oncol,1985,12(suppl):3.
6Early Breast Cancer Trialists Collabrative Group. Ovarian ablation in early breast cancer: overview of the randomized trial[J].Lancet,1996,348(9036):1189.
7Thompson AM, Elton RA, Hawkins RA, et al. PS2 mRNA expression add prognostic information to node status for 6-year survival in breast cancer[J].Br J Cancer,1998,77(3):492.
8Yokota T, Imamura M, Teshima S, et al. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study[J].Anticancer Res, 1999,19(5B):4007.
9Morote J, de Torres I, Caceres C, et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer[J].Int J Cancer, 1999,84(4):421.
10Russell CA, Green SJ, OSullivan J, et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial[J].J Clin Oncol,1997,15(7):2494.
